IP Library Granted Patent US 10,137,133
Granted Patent B2
US 10,137,133 · App. 14/837,831 · Granted Nov 27, 2018

Methods for treatment of diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,137,133
App. No.
14/837,831
Granted
Nov 27, 2018
Kind
B2
Abstract

The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.

Claims (8)

1. A method of treating an inflammatory disease or condition selected from the group consisting of pancreatitis, colitis, inflammatory bowel disease, rheumatoid arthritis, chronic obstructive pulmonary disorder (COPD) and asthma in a human patient, the method comprising administering to the patient 25 mg to 450 mg of a superoxide dismutase mimetic at a rate of at least 100 mg/hr, wherein the superoxide dismutase mimetic corresponds to Formula (GC4419):

and X and Y are independently halo ligands.

2. The method of claim 1 , wherein the superoxide dismutase mimetic is administered in a dosage unit formulation comprising at least 50 mg of the superoxide dismutase mimetic in a container.

3. The method of claim 1 , wherein the superoxide dismutase mimetic is dissolved in a solution comprising about 0.25 mg/mL to about 3.5 mg/mL superoxide dismutase mimetic and contained in an IV bag.

4. The method of claim 1 , wherein X and Y are independently selected from monodentate ligands.

5. The method of claim 1 , wherein the method provides an exposure as measured by an area under the curve (AUC) of at least 4,000 ng-h/mL as calculated from the measurement of the superoxide dismutase mimetic concentration in the patient's plasma.

6. The method of claim 1 , wherein the superoxide dismutase mimetic is administered intravenously.

7. The method of claim 1 , wherein the inflammatory disease or condition is selected from the group consisting of asthma and colitis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2026
From: GALERA LABS, LLC
To: BIOSSIL INC.
Reel/Frame 073778/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2016
From: KEENE, JEFFERY L.; RILEY, DENNIS P.; BEARDSLEY, ROBERT A.
To: GALERA THERAPEUTICS LLC
Reel/Frame 038134/0212 →
CHANGE OF NAME Recorded Mar 30, 2016
From: GALERA THERAPEUTICS LLC
To: GALERA LABS, LLC
Reel/Frame 038134/0294 →